This inventor holds 3 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents and 1 EPO patent. Top assignees: Dso National Laboratories, National University of Singapore. Active years: 2016-2019.
Company Filing History:
3 out of 14 
3 out of 850 
Years Active: 2016-2019
Title: Brendon John Hanson: Innovator in Dengue Virus Research
Introduction
Brendon John Hanson is a notable inventor based in Singapore, recognized for his contributions to medical research, particularly in the field of dengue virus treatment. With a total of three patents to his name, he has made significant strides in developing therapeutic solutions for this viral infection.
Latest Patents
Hanson's latest patents include a human monoclonal antibody with specificity for dengue virus serotype 1 E protein. This invention provides compositions and methods for the treatment or prevention of dengue virus infection in vertebrate subjects. Specifically, it discloses human neutralizing monoclonal antibodies to dengue virus, which are isolated from EBV immortalized B cells derived from patients who have recovered from dengue infection. The methods outlined in the patent detail how to administer these antibodies effectively to reduce, eliminate, or prevent relapse from infection.
Career Highlights
Throughout his career, Brendon John Hanson has worked with prestigious institutions such as the National University of Singapore and DSO National Laboratories. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of his notable coworkers include Paul Macary and Ee Ping Evelyn Teoh, who have also played significant roles in advancing research in related areas.
Conclusion
Brendon John Hanson stands out as an influential inventor in the realm of dengue virus research, with his innovative patents paving the way for new treatment options. His dedication to medical science continues to impact the field positively.